Advertisement
Screener

Xilio Therapeutics, Inc. (XLO) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Xilio Therapeutics, Inc. Investing Cash Flow

Xilio Therapeutics, Inc. (XLO) reported Investing Cash Flow of -$575.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12

  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$19.00K.
  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$556.00K.
  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$95.00K.
  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $0.00.
  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$518.00K.
  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$36.00K.
  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$486.00K.
  • Xilio Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$1.87M.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 month
2026-06-30-$19.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$575.00K
10-Q · filed 2026-08-12
-$670.00K
derived: sum of 3 quarters · filed 2026-08-12
-$670.00K
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$556.00K
10-Q · filed 2026-05-12
-$651.00K
derived: sum of 2 quarters · filed 2026-05-12
-$651.00K
derived: sum of 3 quarters · filed 2026-05-12
-$1.05M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$95.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$95.00K
derived: sum of 2 quarters · filed 2026-03-23
-$496.00K
derived: sum of 3 quarters · filed 2026-08-12
-$518.00K
10-K · filed 2026-03-23
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$401.00K
derived: sum of 2 quarters · filed 2026-08-12
-$423.00K
10-Q · filed 2025-11-13
-$429.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$401.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$423.00K
10-Q · filed 2026-08-12
-$429.00K
derived: sum of 3 quarters · filed 2026-08-12
-$438.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$22.00K
10-Q · filed 2026-05-12
-$28.00K
derived: sum of 2 quarters · filed 2026-05-12
-$37.00K
derived: sum of 3 quarters · filed 2026-05-12
2024-12-31-$6.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
-$15.00K
derived: sum of 2 quarters · filed 2026-03-23
-$36.00K
10-K · filed 2026-03-23
2024-09-30-$9.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$30.00K
10-Q · filed 2025-11-13
2024-06-30-$21.00K
10-Q · filed 2025-08-14
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$0.00
derived: sum of 2 quarters · filed 2025-03-11
-$316.00K
derived: sum of 3 quarters · filed 2025-03-11
-$486.00K
10-K · filed 2025-03-11
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$316.00K
derived: sum of 2 quarters · filed 2024-11-07
-$486.00K
10-Q · filed 2024-11-07
-$995.00K
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$316.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$486.00K
10-Q · filed 2024-08-08
-$995.00K
derived: sum of 3 quarters · filed 2024-08-08
-$1.33M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$170.00K
10-Q · filed 2024-05-14
-$679.00K
derived: sum of 2 quarters · filed 2024-05-14
-$1.01M
derived: sum of 3 quarters · filed 2024-05-14
-$1.78M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$509.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
-$842.00K
derived: sum of 2 quarters · filed 2024-04-01
-$1.61M
derived: sum of 3 quarters · filed 2024-04-01
-$1.87M
10-K · filed 2024-04-01
2022-09-30-$333.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$1.10M
derived: sum of 2 quarters · filed 2023-11-09
-$1.36M
10-Q · filed 2023-11-09
-$1.74M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$771.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$1.02M
10-Q · filed 2023-08-14
-$1.40M
derived: sum of 3 quarters · filed 2023-08-14
-$1.52M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$254.00K
10-Q · filed 2023-05-09
-$632.00K
derived: sum of 2 quarters · filed 2023-05-09
-$746.00K
derived: sum of 3 quarters · filed 2023-05-09
-$1.18M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$378.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
-$492.00K
derived: sum of 2 quarters · filed 2023-03-02
-$930.00K
derived: sum of 3 quarters · filed 2023-03-02
-$1.10M
10-K · filed 2023-03-02
2021-09-30-$114.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$552.00K
derived: sum of 2 quarters · filed 2022-11-09
-$722.00K
10-Q · filed 2022-11-09
-$830.00K
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30-$438.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$608.00K
10-Q · filed 2022-08-09
-$716.00K
derived: sum of 3 quarters · filed 2022-08-09
2021-03-31-$170.00K
10-Q · filed 2022-05-12
-$278.00K
derived: sum of 2 quarters · filed 2022-05-12
2020-12-31-$108.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$2.19M
10-K · filed 2022-03-01
2020-09-30-$2.08M
10-Q · filed 2021-12-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Serina Therapeutics, Inc. (SER)United States$0.054B-2.35
Clene Inc. (CLNN)United States$0.054B-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83